Recent News About Akorn, Incorporated
A federal judge has ordered a group of lawyers to return more than $300,000 in fees they received under a settlement of a shareholder lawsuit they brought against drug manufacturer Akorn, as the judge said the lawsuit amounted to little more than another example of the “racket” of “worthless” shareholder class actions.
From a lawsuit against suburban-based drugmaker Akorn, a settlement has grown in Chicago federal court, which could hand $8 million to lawyers for pursuing the class action suit against Akorn Pharmaceuticals, alleging the company misled investors.
Shareholder suit alleges Akorn, Fresenius merger benefits leadership, doesn't do enough for investors
A group of investors wants a court to keep German pharmaceutical firm Fresenius from buying Illinois drug maker Akorn, saying shareholders won’t get enough from the deal, which is valued at more than $4 billion.